Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Thyroid Cancer, Papillary 1Melanoma 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Administration, Cutaneous × Clear all
NCT03850691 2024-01-17

Radiation and Combination Immunotherapy for Melanoma

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
4 enrolled 11 charts
Dermatologic

Melanoma

NCT01974284 2019-11-25

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

Yale University

Phase NA Terminated
7 enrolled 4 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡